Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Int J Cancer. Author manuscript; available in PMC 2011 June 1.
Published in final edited form as:
PMCID: PMC2847647

Transcription factor co-repressors in cancer biology; roles and targeting


Normal transcription displays a high degree of flexibility over the choice, timing and magnitude of mRNA expression levels that tend to oscillate and cycle. These processes allow for combinatorial actions, feedback control and fine-tuning. A central role has emerged for the transcriptional co-repressor proteins such as NCOR1, NCOR2/SMRT, CoREST and CTBPs, to control the actions of many transcriptional factors, in large part, by recruitment and activation of a range of chromatin remodeling enzymes. Thus, co-repressors and chromatin remodeling factors are recruited to transcription factors at specific promoter/enhancer regions and execute changes in the chromatin structure. The specificity of this recruitment is controlled in a spatial-temporal manner. By playing a central role in transcriptional control, as they move and target transcription factors, co-repressors act as a key driver in the epigenetic economy of the nucleus. Co-repressor functions are selectively distorted in malignancy, by both loss and gain of function and contribute to the generation of transcriptional rigidity. Features of transcriptional rigidity apparent in cancer cells include the distorted signaling of nuclear receptors and the WNTs/β-catenin axis. Understanding and predicting the consequences of altered co-repressor expression patterns in cancer cells has diagnostic and prognostic significance, and also have the capacity to be targeted through selective epigenetic therapies.

Keywords: Co-repressors, transcription, NCOR1, NCOR2/SMRT, Epigenetics

1. Regulation of transcriptional plasticity

1.1. The epigenetic control of transcriptional cycling

A high level of organized complexity underpins homeostasis in humans, central to which are the dexterous and integrated actions of transcriptional networks. Frequently these networks result in transcriptional outputs that oscillate between on and off states. Alternating between these two states can be considered to be a cyclic behavior. As yet the master regulators of these alternating and cycling events remain incompletely understood. Developmental programs display such phasic spatial-temporal regulation, for example, in embryonic vertebrate formation, and combine with extrinsic inputs, to generate the circadian rhythm and metabolic control. This oscillating, or cycling behavior also occurs in response to environmental signals, such as in the regulation of inflammatory genes. The nuclear receptors (NRs) also entrain transcriptional cycling in a wide variety of target genes in response to both intrinsic hormonal and extrinsic dietary derived signals.

Transcriptional cycling arises from the actions of distinct activating and repressing complexes that together allow for fine control of mRNA regulation. The choreography of these actions is tightly regulated and allows these regulatory complexes to recognize, interpret and sustain histone modifications on target gene promoters. The number of histone modifications and their combinatorial nature generates a very diverse and malleable interface platform between DNA and transcription factors (reviewed in1) and is a further driver of transcriptional plasticity. The regulation of histone modifications acts as a type of biological ratchet in which sequential complexes feed forward to initiate and sustain transcription2, 3. It should be borne in mind that very few, if any, transcriptional targets are governed by a single factor, but rather the patterns of transcriptional regulation reflect the integration of multiple factors acting in concert. Collectively, the endpoint of these interactions is the spatial-temporal distribution of boundaries between transcriptionally rich euchromatin and transcriptionally restricted heterochromatin. The boundaries between these chromatin states are cemented further by regulation of CpG island methylation; thus histone modifications and CpG methylation are dynamically intertwined4.

Co-activators and co-repressors significantly regulate the control of transcriptional active and inactive states events respectively. Co-repressors repress transcription by recognizing, initiating, and sustaining repressive chromatin environments and contribute the points of minima and limit the maxima on the waves of transcription cycling and thereby significantly regulate the timing of transcription. Given their role to regulate epigenetic events that underlie transcriptional inactivation, the structurally diverse yet phenotypically related co-repressor proteins have emerged as key players in cancer etiology.

1.2. Transcriptional Rigidity In Cancer

Post-genomic analyses of major transcription factor families, in both malignant and non-malignant cell types, have resulted in a revision of understanding. Transcription factor actions in cancer cell systems appear to exhibit a restricted repertoire of the dexterity and plasticity displayed by normal cell systems. The evolution of a restricted malignant transcriptome is seen clearly in the NR superfamily, but is also apparent in the MYC and AP-1 networks (reviewed in5).

NRs form one of the largest and most well understood superfamily of transcription factors. Generally, unliganded NRs repress transcription of targets whereas agonist binding promotes transcription; binding of NRs to either co-repressor or co-activator complexes respectively is essential to mediate these effects (reviewed in6). NR complex composition varies resulting in diverse patterns of transcriptional cycling, in terms of amplitude and magnitude. That is, the constituents of the NR complex change during the transcriptional cycle at different response elements. The implication of this is that the individual complexes both recognize and impart separate patterns of histone modifications and local chromatin structure to allow, for example, for chromatin looping7, 8.

The loss of transcriptional plasticity and the evolution of a restricted transcriptome are displayed by NRs in malignancy. A role for the androgen receptor (AR) in driving proliferation of epithelial progenitor cells within the prostate is well established, for example, through co-operation with WNT and mTOR pathways. However, the AR also controls cell cycle progression and differentiation through direct regulation of gene targets such as CDKN1A and NKX3.19. Genome wide studies have revealed that during cancer progression the AR transcriptome becomes altered and evolves towards the targeting of different promoters of genes that drive proliferation10, 11. For example, the TMPRSS2/ETS oncogenic fusion protein is a common critical event in prostate cancer, precisely because the TMPRSS2 promoter is sustained in an AR responsive state11 whereas the AR responsiveness of other targets such as NKX3.1 becomes silenced12. Equally in a range of solid tumors and myeloid leukemia, NRs that normally exert mitotic restraint, such as the VDR, RARs and PPARs, become skewed, with selective silencing of anti-proliferative target genes13-18. Combined, oncogenic transcriptional rigidity reflects the simultaneous distorted regulation of target loci such that proliferative and survival signals are enhanced and anti-mitotic inputs are either limited or lost. Co-repressor proteins contribute significantly to disruption of these processes.

2. Co-repressor roles in driving transcriptional rigidity

2.1. Nuclear receptor co-repressor 1 (NCOR1) and nuclear receptor co-repressor 2/ silencing mediator for retinoid and thyroid hormone receptors (NCOR2/SMRT)

NCOR-1 and NCOR2/SMRT are proto-typical co-repressors, cloned in parallel in 1995 by the groups of Rosenfeld19 and Evans20 respectively. These large regulatory proteins of approximately 270 kDa were isolated using NRs as bait to capture interacting proteins. Both proteins display a number of functional motifs including the NCOR2/SMRT and NCOR1 conserved (SNC), and SWI3, ADA2, NCOR1 and TFIIIB (SANT) domains. While the first SANT domain (SANT1) is dispensable, SANT2 is essential for interaction with HDAC3, HDAC1 and CoREST functions. NCOR1 also interacts allosterically with HDAC3 via the deacetylase interaction domain (DAD). There are three different Interaction Domains (IDs) in NCOR1 (N1-3) and NCOR2/SMRT (S1-3), which contain similar motifs to the co-activators' NR box, and are named “CoRNR box”.

Generally, in the absence of ligand, NR conformation facilitates interaction in large co-repressor complexes (~2.0 MDa)21. However more recently mechanisms have emerged whereby activated transcription factors can recruit NCOR1 and NCOR2/SMRT leading to active gene silencing. For example, ligand-dependent sumoylation of the PPAR-γ ligand-binding domain recruits the NCOR1 and HDAC3 complex to drive transrepression22. In turn, this prevents NCOR1 recruitment to the ubiquitylation/19S proteasome and promoter clearing.

The list of NCOR1 and NCOR2/SMRT targeted transcription factors is diverse and includes not only NRs, but also MAD/MXI, MYOD, ETO, CBF, TFIIB, AP-1 members and NF-κB factors. Reflecting this large number of transcription factor interactions, murine knockouts of Ncor1 and Ncor2/Smrt are embryonically lethal. More recently, stem cell components from Ncor1−/− and Ncor2/Smrt−/− mice and conditional approaches have revealed a network of interactions that includes both unique and shared targets23. Similarly, a knock-in approach circumvented the embryonic lethality and allowed the specific disruption of the interaction of Ncor2/Smrt with NRs. These models revealed dramatically enhanced differentiation rates, notably of adipocytes mediated by PPARγ24. NCOR2/SMRT also regulates FOXP1 that in turn governs a cohort of genes necessary for proper myocardial development. In wild type hearts, Ncor2/Smrt and Foxp1 are detected on the promoter of Cckn1a (encodes p21(waf1/cip1)) together with H3K9me2 enrichment, which represses p21(waf1/cip1) expression. Consequently, p21(waf1/cip1) levels are basally elevated in either Ncor2/Smrt or FoxP knockout animals, leading to a block of proliferation and thinned myocardium25.

Well established oncogenic roles for NCOR1 and NCOR2/SMRT have been elucidated in acute promyelocytic leukaemia that results from a fusion between the NR, RARα, and either the promyelocytic leukaemia (PML) or promyelocytic leukaemia zinc finger (PLZF) genes16. Both chimeric proteins sustain NCOR1 interactions and consequently RARα-mediated cell differentiation is blocked, in part, as a result of maintaining a condensed chromatin structure around the promoters of RARα target genes that govern normal hematopoietic differentiation. In the PML-RAR fusion, this can be overcome by pharmacological dosing with retinoic acid. The PLZF-RAR fusion is resistant to retinoic acid alone and treatment with a combination of retinoic acid and HDAC inhibitors has shown promising results. Similarly, in acute myeloid leukemia (AML), the AML1/ETO fusion protein promotes leukemogenesis by recruiting NCOR1 and again impeding transcriptional regulation26. The importance of NCOR1 binding in the treatment of these disease states exemplifies the relevance of the co-repressors in firstly driving critical oncogenic events, but secondly providing a rational targeted strategy towards HDACs.

Expression profiling in solid tumors has revealed altered NCOR1 and NCOR2/SMRT expression and localization, for example in breast, bladder, and prostate cancers13, 17, 27-30. However, to date, uncertainty remain over their precise role in solid tumors, especially in the case of breast and prostate cancers where the etiology of disease is intimately driven by the actions of steroid hormone NRs. Indeed the ability of the ligand free NR conformation to bind NCOR1 and NCOR2/SMRT is central to therapeutic exploitation with receptor antagonists such as Tamoxifen in the case of breast cancer. Therefore ambiguity exists over the extent and timing of NCOR1 and NCOR2/SMRT expression changes, as they relate to initiation and progression of disease. Secondly, it remains unclear how changes in NCOR1 and NCOR2/SMRT expression relate to different NRs and other transcription factors that exert either pro- or anti-mitotic and survival effects. Resolving these ambiguities has significant therapeutic implications in terms of targeting co-repressors as either epigenetic mono-therapies using HDAC inhibitors or in combinations with transcription factor targeting.

In prostate cancer cells elevated levels of NCOR2/SMRT have been detected and suppress VDR responsiveness13. Similarly, PPAR actions are disrupted and can be targeted selectively by using HDAC inhibitor co-treatments31, 32. More specifically elevated NCOR1, and to a lesser extent NCOR2/SMRT correlated with, and functionally drove, the selective insensitivity of PPARα/γ receptors towards dietary derived and therapeutic ligands32 most clearly in androgen-independent disease. Similar roles for NCOR1 and NCOR2/SMRT appear in the development of breast cancer. NCOR1 and NCOR2/SMRT levels appear unchanged in estrogen-dependent disease that responds to Tamoxifen, whereas they are down-regulated in murine models and patients samples of emergent Tamoxifen resistance27. ERα activation initiates a feed-forward effect on transcription by initiating NCOR1 proteosomal degradation. Possibly reflecting the loss of this negative control loop, elevated levels of NCOR1 occur in ERα negative disease and in turn attenuate anti-mitotic actions of VDR. Again, this molecular lesion can be targeted in ERα negative breast cancer cell lines with co-treatments of VDR ligand (e.g. 1α,25(OH)2D3) plus HDAC inhibitors resulting in selective re-expression of VDR target genes, notably VDUP1 and GADD45A17. Combined the studies in breast and prostate cancer suggest NR specificity of interactions with co-repressors. NCOR1 appears to be involved in the regulation of receptors such as the VDR and PPARs and NCOR2/SMRT with steroid hormone receptors and reflect the emergent specificities of NR interactions in the murine knockout models.

Given the list of targeted transcription factors it is unlikely that deregulation of NR actions is the only oncogenic impact of altered NCOR1 and NCOR2/SMRT expression. These questions are perhaps more clearly addressed in cancers where the biology is not so exquisitely associated with NRs, such as colon cancer. Considering post-translational modifications that regulate NCOR1 and NCOR2/SMRT activity reveals other de-regulated aspects of these co-repressors. Phosphorylated NCOR133 and NCOR2/SMRT translocate out of the nucleus. NCOR1 and NCOR2/SMRT impede β-catenin binding to LEF/TCF target genes such as CCND1, therefore mediating suppression of TCF4 transcriptome. Consequently, there appears to be increased co-repressor cytoplasmic export and location in colon cancer34-36. Similarly, roles have emerged for interleukin-1b to drive NCOR1 export from the nucleus37 allowing transactivation mediated in part by the TIP60 co-activator complex of a specific subset of nuclear factor-kappa-B (NF-κB)-regulated genes. Furthermore, enhanced NF-κB signaling also leads to NCOR1 and NCOR2/SMRT phosphorylation that enhances further cytoplasmic export. Also, repression domains (RD1-3) at the N-terminal region facilitate interaction with TBL1 and TBLR138 leading to ubiquitination and therefore governs co-repressor half-life of the complex. To-date it remains unclear if the capacity of TBL1/TBLR1 to initiate degradation of NCORs is distorted in malignancy.

Together these findings considering different transcription factors suggests that both enhanced and impeded NCOR1 and NCOR2/SMRT activity occur in cancer and will require comprehensive analyses to identify the critical transcription factor interactions. Similar contextual aspects to function have emerged for other co-repressors as outlined below. Generation of this knowledge concerning the timing and specificity of interactions with transcription factors and the epigenetic machinery may pave the way for more targetted therapeutic exploitation.


The C-terminal domain of viral E1A proteins were used as bait to identify interacting proteins including CTBP139 and CTBP240 that in turn modulate multiple aspects of transformation. For example CTBP1 and CTBP2 co-localize with polycomb group complexes thereby leading to gene silencing41. CTBP1 also displays dehydrogenaze activity and appears to serve as a cellular redox sensor with repression being acutely sensitive to NAD+/NADH levels42. CTBPs interact with transcription factors through a PXDLS motif to generates a large repressive complex, again, similar to the NCORs, in the order of 1.3 to 1.5 MDa, including components such as REST/CoREST, HDAC1 and HDAC2. More recently, to underline the co-operative role between co-repressor complexes, Rosenfeld and co-workers have established that CTBPs and NCOR2/SMRT complexes together mediate a combined transcriptional repression checkpoint that must be overcome to initiate transcription43.

Like the NCORs, the oncogenic actions of CTBPs also appear to be context-dependent. CTBP1 is implicated in the transrepression events mediated by ERα44, 45 and, again, its deregulation suggests a role that distorts and restricts the normal flexibility of receptor transcription. For example, CTBP1 was found to interact in-vitro and in-vivo with the zinc-finger protein ZNF366 and mediate selective estrogen-dependent and HDAC-mediated repression of ERα target genes in breast cancer cells46. Similarly, in hepatocellular carcinoma, CTBP1 binds to the INK4 family member, p19INK4D, suppressing its expression and leading to increased invasiveness47. Other workers have focused on the oncogenic role of WNT signaling in colon tumorigenesis, and demonstrated that upregulation of CTBP1 is a critical step downstream of loss of APC either prior to, or independently of, β-catenin nuclear localization further supporting a role for establishing transcriptional rigidity in the oncogenic process48. By contrast, CTBP1 is lost in melanoma cells allowing increased expression of a number of LEF/TCF target genes resulting in increased invasiveness49. Thus the specificity and timing of transcription factor interaction is critical to evaluate the CTBPs oncogenic properties.


REST/CoREST is present in a wide variety of cell types and complexes with RE1 silencing transcription factor/neural-restrictive silencing factor (REST/NRSF) to block expression of key target genes50 and, in turn, is part of a complex with HDAC1, -2, BHC80, BRAF35 and the histone demethylase KDM1/LSD1. The interaction with this KDM illustrates further aspects to co-repressor distortion.

KDM1/LSD1 recognizes methylated histone lysine residues, notably H3K4 and K9. However the demethylation of these residues leads to opposite phenotypic events; demethylation of H3K4 is associated with gene repression51, whereas demethylation of H3K9 leads to gene activation52. Therefore the specificity of complex sequestration for this important enzyme is pivotal. Specificity is in part contributed by the action of site-specific tri-demethylases whose actions govern the availability of the respective di-methylated substrate for KDM1/LSD1. Family members of the JARID proteins target H3K4me353 whereas JMJD2 members target H3K9me354, and these proteins themselves have emerging roles in cancer etiology. KDM1/LSD1 sequestration, for example into the REST/CoREST complex that promotes demethylation of H3K4me2 at active loci and subsequent recruitment of MeCP2 to facilitate CpG island methylation and the generation of repressive chromatin structure51, 55 (Figure 1).

Figure 1
A model for the deregulation of co-repressors leading to stable targeted repression

Other CoREST complex functions include association with the chromatin-remodeling complex, SWI/SNF to lead to enhanced tumorigenicity56. CoREST can also form a larger complex with ZNF217, which is a Kuppel-like transcription factor, and CTBP1/2. Specifically, ZNF217 is a strong candidate oncogene found in breast cancer at the 20q13.2 amplicon and there appears to be a link between over-expression of ZNF217 and the loss of TGF-β responsiveness in breast cancer leading to the transcriptional suppression of targets such as p15ink4,57.


RUNX transcription factors were originally identified in embryonal carcinoma cells after they underwent RAR induced differentiation. The α-subunits (RUNX1/AML1/PEBP2αB, RUNX2/PEBP2αA or RUNX3/PEBP2αC) heterodimerize with the β subunit of PEBP2/CBF to increase DNA affinity. Although RUNX2 represents the best-understood family member, its actions are also highly context-dependent. RUNX2 haploinsufficiency is associated with cleidocranial dysplasia - a disorder characterized by a range of skeletal abnormalities. This phenotype is in part mediated by the loss of interaction of RUNX2 with the CDKN1A promoter activity, that is mediated by members of the transducin-like enhancer of split (TLE)/Groucho (Grg) family of proteins58, 59. Its carboxy terminal has also been shown to be a potent repressor, for example, by recruitment of HDAC6 from the cytoplasm to chromatin59.

The direct oncogenic potential of RUNX2 has been demonstrated by Vaillant et al creating a transgenic mouse with Runx2 under the control of the Cd2 promoter, that perturbed thymocyte development and lead to spontaneous lymphoma60. Increased expression of RUNX2 has also been observed in breast cancer cell lines and is thought to be involved in bone metastasis; a possible mechanism of action that reflects the significant bone biology of RUNX2. RUNX2 expression appears to be downstream of WNT signaling61 and forms a RUNX2 enriched network, for example in prostate cancer62, and therefore this co-repressor has been proposed as a critical novel drug target63.


Several key co-repressors have been identified in breast cancer. For example the MTA gene family has been examined in detail in breast cancer and linked to ERα signalling64 For more detail the reader is referred to an excellent review on MTA1 and MTA365. Another co-repressor identified in breast cancer is BRMS1, which was identified as part of strategy to reveal metastasis suppressors66, 67, by examining frequently deleted genomic regions in metastatic breast carcinoma. Critically, studies on BRMS1 illustrate the importance of loss of function of co-repressors in the oncogenic process. The protein is approximately 28.5 kDa with several phosphorylation sites, two functional NLS and interacts, for example, with Retinoblastoma Protein-1, the mSin3-HDAC complex and Hsp90. BRMS1 complexes modte ula NF-κB actions by blocking IκBα (inhibitor of NFκB68) phosphorylation and degradation and in turn suppressing NF-κB activity. BRMS1 participates in the direct repression of the RelA/p65 subunit via HDAC1-dependent deacetylation. Consequently, BRMS1 knockdown allows recruitment of acetylated-RelA/p65 to NF-κB-dependent anti-apoptotic genes69, 70. More recently it has emerged that other key targets regulated by BRMS1, that contribute to metastasis suppression, are microRNAs including miR-14671.


Another example of co-repressor loss of function leading to malignancy is illustrated by Scaffold/Matrix-Associated Region-1 (SMAR1)72. SMAR1 acts with Cux, either synergistically or independently, as transcriptional repressor for the Eβ enhancer. Studies have demonstrated that SMAR1 also forms heterocomplexes with HDAC1/SIN3 and pocket Rbs (p107, p130). Thus, depletion of SMAR1 generates an open chromatin structure as demonstrated by the acetylated histones at the CCND1 promoter73 indicating an alternative mechanism of cell cycle deregulation in cancer cells. Reflecting this, SMAR1 is down-regulated in malignant breast cancer tissues leading to a more active TGFβ signaling and promoting invasion with prognostic significance74. By contrast, over-expression of SMAR1 significantly delayed tumor growth in mice through direct interaction with p53 and downstream activation of p21(waf1/cip1),75.


ZBRK1/ZNF350 undergoes homo-oligomerization and a C-terminal domain represses transcription in a BRCA1-dependent, HDAC-dependent and promoter specific manner, for example of GADD45A76. Similar to other co-repressors, this complex interacts with downstream target genes, such as the HP1 family of heterochromatin-associated proteins thereby leading to stable silencing (Figure1). This repression is present in the absence of DNA damage whereas upon UV-methyl methanesulfonate treatment the ubiquitin-proteasome pathway mediates ZBRK1/ZNF350 BRCA1-independent degradation77. This damage-dependent de-repression of cell cycle gatekeepers exerts a tight control over cell proliferation. ZBRK1/ZNF350 also forms a repressor complex on the Angiotensin-1 (ANG-1) promoter and loss of expression is consistent with Brca1-deficient mice models where Ang1 is over-expressed and accelerates tumor growth rate78.

Altered expression of ZBRK1/ZNF350, both over-expression and under-expression, has been found on primary breast carcinoma, and not surprisingly mRNA levels are not prognostic. However, a significant correlation exists between two ZBRK1/ZNF350 polymorphisms and mRNA levels79 and expression in colon cancer is reduced80.


NRIP1/RIP140 was first identified as an ERα interacting protein that binds in a ligand-dependent manner to a wide range of NRs to limit activation. At higher ligand concentrations, NRIP/RIP140 binding is associated with ERα trans-repression functions. To achieve these functions it interacts with HDAC1 and HDAC3 as well as HDAC2, -5 and -6, possibly in a redundant manner


The primary role of co-repressors complexes is to re-model chromatin and attenuate the kinetics of transcriptional initiation. In malignancy elevated co-repressor expression leads to suppressed gene expression, most likely by suppressing the ability to initiate the positive aspects of mRNA cycling, as illustrated by NCORs. It has also emerged that loss of co-repressor expression, such as BRMS1, leads to the opposite, enhanced transcriptional activity. The specific details and consequences of co-repressor interactions are often more nuanced, depending on the interacting transcription factor and gene (or miRNA) being targeted. However the consequence of de-regulated co-repressor function is the same; normal plastic transcriptional cycling is lost and a state of rigidity emerges. Reflecting the biological importance of this control, the number of co-repressor proteins continues to grow, for example NRIP181, 82, COPS2/TRIP15/Alien83, TCERG1/CA15084, SLIRP85 and LCOR86 are well-characterized biologically but their roles in cancer remain to be clarified.

The transcriptional distortion and rigidity in cancer induced by changes of co-repressor expression, localization and interactions is mediated by the actions of a diverse number of histone modifying enzymes. It is likely that a greater understanding of how histone modifications combine1 in a so-called histone code87 will help to reveal further the specificities of target gene regulation. Of the varied histone modifications, deacetylation and demethylation are intimately linked and are significant mediators of transcriptional repression. In the absense of DNA methylation, these inter-relationships are highly dynamic, with target gene promoters often poised to be subsequently pushed towards a fully active, or a more stably repressed state. For example, non-expressed genes retain low level RNA POLII association, simultaneous HDAC and HAT activity, and modest transcriptional initiation88. It seems that the presence of H3K4 methylation perhaps holds these promoters in this poised state.

Elevated co-repressor expression can act to suppress this poised state. Sustained repressive histone modifications also have a significant role to restrict transcriptional plasticity further as they attract DNA methylating events associated with stable gene silencing. For example, NCOR1 and NCOR2/SMRT complexes deacetylate H3K9ac and thereby facilitate H3K9 methylation by several mechanisms. The loss of acetylation makes K9 accessible to methylation for example by SUV39H1. H3K9me2 status is subsequently targeted by HP1 and leads to further stable gene silencing through recruitment of DNA methyltransferase 1 (DNMT1) and DNA methylation of adjacent CpG islands. Similarly NCOR1-mediated gene silencing involves interaction with Kaiso, a methylation dependent transcriptional repressor that allows interaction with the methylated CpGs present in the promoter of target genes, silencing their transcription89. Recently, histone activating marks and CpG methylation have emerged to be even more dynamically intertwined than previously thought, with lower density CpG regions transiently regulated, for example during the transcriptional cycle of NRs90 adding further potential control to the plasticity of transcription. One possible consequence of increased CpG island hypermethylation is the generation of stably maintained transcriptional rigidity displayed in cancer cell systems. Thus, it is reasonable to suggest that elevated expression of co-repressors favors histone modifications that in turn are targets for the DNA methylation machinery and lead selectively to regions of the genome acquiring heterochromatin like characteristics. These repressive states are fixed in a more stable and heritable manner and thereby limit the choice of promoters (Figure 1). The loss of co-repressor expression and/or functions theoretically will induce the opposite chromatin states, but this remains to be established formally.

Importantly these epigenetic lesions are individually highly targetable with clinically available small molecular weight inhibitors targeted to specific histone deacetylation events and more recently this has been extended to include histone methylation events91, coupled with agents that target CpG methylation (reviewed in92). Thus comprehensive understanding of the key co-repressors in malignancy, delineating the key transcription factors interactions and the critical targets that are thereby dis-regulated may have considerable prognostic utility, specifically through the capacity to stratify patients for specific tailored epigenetic therapies.


MJC acknowledges the support of NucSys, a European Community FP6- Marie Curie Research Training Network, the Biotechnology and Biological Sciences Research Council, and in part, support from National Institute of Health grants R01 CA095367-06 and 2R01-CA-095045-06, and the NCI Cancer Center Support Grant to the Roswell Park Cancer Institute [CA016056].

List of Abbreviations

Androgen receptor
Bromo-adjacent homology
Breast cancer metastasis suppressor 1
C-terminal-binding protein
Deacetylase interaction domain
Docosahexaenoic acid
DNA methyltransferase
Egl-27 and MTA1 homology
Estrogen receptor
E-twenty six family of transcription factors
Farnesoid X-activated receptor
Histone deacetylase
Interaction domain
Ligand-dependent nuclear receptor corepressor
Lymphoid Enhancer-Binding Factor 1/Transcription Factor, T Cell-Specific
Matrix attachment region binding proteins
Metastasis-associated gene
Nuclear receptor co-repressor 1
Nuclear receptor co-repressor 2/Silencing mediator of retinoid and thyroid hormone receptors
Nuclear localization signal
NK homeobox, family 3, A
Nuclear receptor
Peroxisome proliferator activated receptor
Pro-X-Asp-Leu-Ser motif
Retinoic acid receptor
RE1 silencing transcription factor/ corepressor
Repression domain
Neural-restrictive silencing factor
Nuclear receptor-interacting protein 1
RNA recognition motif
Retinoid X receptor
RUNT-related transcription factor
SWI3, ADA2, NCOR1 and TFIIIB domain
NCOR2/SMRT/HDAC1 associated repressor
SRA stem-loop interacting protein
Scaffold/Matrix-associated region 1
Steroid receptor activator
transducin (beta)-like 1X-linked/ transducin (beta)-like 1X-linked receptor 1
Transcription elongation regulator 1
Transmembrane Protease, Serine
Thyroid receptor
Vitamin D receptor
Zinc finger and BRCA1-interacting protein with a KRAB domain 1
1left angle bracket25(OH)2D3
1left angle bracket,25dihydroxyvitaminD3


The authors declare that there is no conflict of interest that would prejudice the impartiality.


1. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 2007;14:1025–40. [PubMed]
2. Dobrzynski M, Bruggeman FJ. Elongation dynamics shape bursty transcription and translation. Proceedings of the National Academy of Sciences of the United States of America. 2009 [PubMed]
3. Degenhardt T, Rybakova KN, Tomaszewska A, Mone MJ, Westerhoff HV, Bruggeman FJ, Carlberg C. Population-level transcription cycles derive from stochastic timing of single-cell transcription. Cell. 2009;138:489–501. [PubMed]
4. Mohn F, Schubeler D. Genetics and epigenetics: stability and plasticity during cellular differentiation. Trends Genet. 2009;25:129–36. [PubMed]
5. Thorne JL, Campbell MJ, Turner BM. Transcription factors, chromatin and cancer. Int J Biochem Cell Biol. 2009;41:164–75. [PubMed]
6. Rosenfeld MG, Lunyak VV, Glass CK. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006;20:1405–28. [PubMed]
7. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell. 2003;115:751–63. [PubMed]
8. Saramaki A, Diermeier S, Kellner R, Laitinen H, Vaisanen S, Carlberg C. Cyclical chromatin looping and transcription factor association on the regulatory regions of the p21 (CDKN1A) gene in response to 1alpha ,25-dihydroxyvitamin D3. J Biol Chem. 2009 [PMC free article] [PubMed]
9. Abdulkadir SA, Magee JA, Peters TJ, Kaleem Z, Naughton CK, Humphrey PA, Milbrandt J. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol.Cell Biol. 2002;22:1495–503. [PMC free article] [PubMed]
10. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G. Evolution of the Androgen Receptor Pathway during Progression of Prostate Cancer. Cancer Res. 2006;66:5012–20. [PubMed]
11. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009;138:245–56. [PMC free article] [PubMed]
12. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, Gasser TC, Koivisto P, Lack EE, Kononen J, Kallioniemi OP, Gelmann EP. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 2000;60:6111–5. [PubMed]
13. Khanim FL, Gommersall LM, Wood VH, Smith KL, Montalvo L, O'Neill LP, Xu Y, Peehl DM, Stewart PM, Turner BM, Campbell MJ. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Oncogene. 2004;23:6712–25. [PubMed]
14. Rashid SF, Moore JS, Walker E, Driver PM, Engel J, Edwards CE, Brown G, Uskokovic MR, Campbell MJ. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene. 2001;20:1860–72. [PubMed]
15. Abedin SA, Thorne JL, Battaglia S, Maguire O, Hornung L, Doherty AP, Mills IG, Campbell MJ. Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Carcinogenesis. 2009 [PMC free article] [PubMed]
16. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Jr., Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811–4. [PubMed]
17. Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, Mansi J, Stewart PM, O'Neill LP, Turner BM, Colston KW, Campbell MJ. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res. 2006;12:2004–13. [PubMed]
18. Ting HJ, Bao BY, Reeder JE, Messing EM, Lee YF. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Mol Cancer Res. 2007;5:967–80. [PubMed]
19. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 1995;377:397–404. [PubMed]
20. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377:454–7. [PubMed]
21. Li J, Wang J, Nawaz Z, Liu JM, Qin J, Wong J. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 2000;19:4342–50. [PubMed]
22. Tiefenbach J, Novac N, Ducasse M, Eck M, Melchior F, Heinzel T. SUMOylation of the corepressor N-CoR modulates its capacity to repress transcription. Molecular biology of the cell. 2006;17:1643–51. [PMC free article] [PubMed]
23. Jepsen K, Solum D, Zhou T, McEvilly RJ, Kim HJ, Glass CK, Hermanson O, Rosenfeld MG. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature. 2007;450:415–9. [PubMed]
24. Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, Cohen RN. The nuclear receptor corepressors NCoR and SMRT decrease PPARgamma transcriptional activity and repress 3T3-L1 adipogenesis. J.Biol.Chem. 2005 [PubMed]
25. Jepsen K, Gleiberman AS, Shi C, Simon DI, Rosenfeld MG. Cooperative regulation in development by SMRT and FOXP1. Genes Dev. 2008;22:740–5. [PubMed]
26. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell. 2000;5:811–20. [PubMed]
27. Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bieche I. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin.Cancer Res. 2003;9:1259–66. [PubMed]
28. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, Hamaguchi M, Hara Y, Kobayashi S, Iwase H. NCOR1 mRNA is an independent prognostic factor for breast cancer. Cancer Lett. 2005 [PubMed]
29. Abedin SA, Thorne JL, Battaglia S, Maguire O, Hornung LB, Doherty AP, Mills IG, Campbell MJ. Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells. Carcinogenesis. 2009;30:449–56. [PMC free article] [PubMed]
30. Kim JY, Son YL, Lee YC. Involvement of SMRT Corepressor in Transcriptional Repression by the Vitamin D Receptor. Mol Endocrinol. 2009;23:251–64. [PubMed]
31. Chang TH, Szabo E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin.Cancer Res. 2002;8:1206–12. [PubMed]
32. Battaglia S, Thorne J, Maguire O, Hornung L, McCabe C, Bunce CM, Campbell MJ. Elevated NCOR1 disrupts PPAR signaling in prostate cancer and forms a targetable epigenetic lesion. 2009 [PMC free article] [PubMed]
33. Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP. A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol. 2006;24:1285–92. [PubMed]
34. Song LN, Gelmann EP. Silencing mediator for retinoid and thyroid hormone receptor and nuclear receptor corepressor attenuate transcriptional activation by the beta-catenin-TCF4 complex. J Biol Chem. 2008;283:25988–99. [PubMed]
35. Fernandez-Majada V, Pujadas J, Vilardell F, Capella G, Mayo MW, Bigas A, Espinosa L. Aberrant cytoplasmic localization of N-CoR in colorectal tumors. Cell Cycle. 2007;6:1748–52. [PubMed]
36. Hoberg JE, Yeung F, Mayo MW. SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell. 2004;16:245–55. [PubMed]
37. Baek SH, Ohgi KA, Rose DW, Koo EH, Glass CK, Rosenfeld MG. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. Cell. 2002;110:55–67. [PubMed]
38. Yoon HG, Chan DW, Huang ZQ, Li J, Fondell JD, Qin J, Wong J. Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. EMBO J. 2003;22:1336–46. [PubMed]
39. Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, Chinnadurai G. A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J. 1993;12:469–78. [PubMed]
40. Katsanis N, Fisher EM. A novel C-terminal binding protein (CTBP2) is closely related to CTBP1, an adenovirus E1A-binding protein, and maps to human chromosome 21q21.3. Genomics. 1998;47:294–9. [PubMed]
41. Sewalt RG, Gunster MJ, van der Vlag J, Satijn DP, Otte AP. C-Terminal binding protein is a transcriptional repressor that interacts with a specific class of vertebrate Polycomb proteins. Mol Cell Biol. 1999;19:777–87. [PMC free article] [PubMed]
42. Kumar V, Carlson JE, Ohgi KA, Edwards TA, Rose DW, Escalante CR, Rosenfeld MG, Aggarwal AK. Transcription corepressor CtBP is an NAD(+)-regulated dehydrogenase. Mol Cell. 2002;10:857–69. [PubMed]
43. Perissi V, Scafoglio C, Zhang J, Ohgi KA, Rose DW, Glass CK, Rosenfeld MG. TBL1 and TBLR1 phosphorylation on regulated gene promoters overcomes dual CtBP and NCoR/SMRT transcriptional repression checkpoints. Mol Cell. 2008;29:755–66. [PMC free article] [PubMed]
44. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC, Hall GF, Wang Q, Bekiranov S, et al. Genome-wide analysis of estrogen receptor binding sites. Nat.Genet. 2006;38:1289–97. [PubMed]
45. Stossi F, Madak-Erdogan Z, Katzenellenbogen BS. Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. Mol Cell Biol. 2009;29:1749–59. [PMC free article] [PubMed]
46. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P, Kindle KB, Heery DM, Parker MG, Buluwela L, Kamalati T, Ali S. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res. 2006;34:6126–36. [PMC free article] [PubMed]
47. Chen YW, Paliwal S, Draheim K, Grossman SR, Lewis BC. p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein. Cancer Res. 2008;68:476–82. [PMC free article] [PubMed]
48. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW, Jones DA. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell. 2009;137:623–34. [PMC free article] [PubMed]
49. Bosserhoff AK, Echtenacher B, Hein R, Buettner R. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res. 2001;11:417–21. [PubMed]
50. Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, Altshuller YM, Frohman MA, Kraner SD, Mandel G. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell. 1995;80:949–57. [PubMed]
51. Lee MG, Wynder C, Cooch N, Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature. 2005;437:432–5. [PubMed]
52. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437:436–9. [PubMed]
53. Pasini D, Hansen KH, Christensen J, Agger K, Cloos PA, Helin K. Coordinated regulation of transcriptional repression by the RBP2 H3K4 demethylase and Polycomb-Repressive Complex 2. Genes Dev. 2008;22:1345–55. [PubMed]
54. Couture JF, Collazo E, Ortiz-Tello PA, Brunzelle JS, Trievel RC. Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase. Nat Struct Mol Biol. 2007;14:689–95. [PubMed]
55. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119:941–53. [PubMed]
56. Watanabe H, Mizutani T, Haraguchi T, Yamamichi N, Minoguchi S, Yamamichi-Nishina M, Mori N, Kameda T, Sugiyama T, Iba H. SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene. 2006;25:470–9. [PubMed]
57. Thillainadesan G, Isovic M, Loney E, Andrews J, Tini M, Torchia J. Genome analysis identifies the p15ink4b tumor suppressor as a direct target of the ZNF217/CoREST complex. Mol Cell Biol. 2008;28:6066–77. [PMC free article] [PubMed]
58. Wang W, Wang YG, Reginato AM, Glotzer DJ, Fukai N, Plotkina S, Karsenty G, Olsen BR. Groucho homologue Grg5 interacts with the transcription factor Runx2-Cbfa1 and modulates its activity during postnatal growth in mice. Dev Biol. 2004;270:364–81. [PubMed]
59. Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS, Li X. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol. 2002;22:7982–92. [PMC free article] [PubMed]
60. Vaillant F, Blyth K, Terry A, Bell M, Cameron ER, Neil J, Stewart M. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene. 1999;18:7124–34. [PubMed]
61. Liu XH, Kirschenbaum A, Yao S, Liu G, Aaronson SA, Levine AC. Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer research. 2007;67:5747–53. [PubMed]
62. Altieri DC, Languino LR, Lian JB, Stein JL, Leav I, van Wijnen AJ, Jiang Z, Stein GS. Prostate cancer regulatory networks. J Cell Biochem. 2009;107:845–52. [PMC free article] [PubMed]
63. Chua CW, Chiu YT, Yuen HF, Chan KW, Man K, Wang X, Ling MT, Wong YC. Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform. Clin Cancer Res. 2009;15:4322–35. [PubMed]
64. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell. 2003;113:207–19. [PubMed]
65. Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009;26:215–27. [PubMed]
66. Seraj MJ, Samant RS, Verderame MF, Welch DR. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer research. 2000;60:2764–9. [PubMed]
67. Phillips KK, Welch DR, Miele ME, Lee JH, Wei LL, Weissman BE. Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11. Cancer research. 1996;56:1222–7. [PubMed]
68. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science. 1988;242:540–6. [PubMed]
69. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nature reviews. 2005;5:749–59. [PubMed]
70. Liu Y, Smith PW, Jones DR. Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis. Mol Cell Biol. 2006;26:8683–96. [PMC free article] [PubMed]
71. Edmonds MD, Hurst DR, Vaidya KS, Stafford LJ, Chen D, Welch DR. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int J Cancer. 2009 [PMC free article] [PubMed]
72. Birot A, Duret L, Bartholin L, Santalucia B, Tigaud I, Magaud J, Rouault J. Identification and molecular analysis of BANP. Gene. 2000;253:189–96. [PubMed]
73. Rampalli S, Pavithra L, Bhatt A, Kundu TK, Chattopadhyay S. Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex. Mol Cell Biol. 2005;25:8415–29. [PMC free article] [PubMed]
74. Pavithra L, Singh S, Sreenath K, Chattopadhyay S. Tumor suppressor SMAR1 downregulates Cytokeratin 8 expression by displacing p53 from its cognate site. Int J Biochem Cell Biol. 2009;41:862–71. [PubMed]
75. Kaul R, Mukherjee S, Ahmed F, Bhat MK, Chhipa R, Galande S, Chattopadhyay S. Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice. International journal of cancer. 2003;103:606–15. [PubMed]
76. Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen PL, Boyer TG, Lee WH. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell. 2000;6:757–68. [PubMed]
77. Yun J, Lee WH. Degradation of transcription repressor ZBRK1 through the ubiquitin-proteasome pathway relieves repression of Gadd45a upon DNA damage. Mol Cell Biol. 2003;23:7305–14. [PMC free article] [PubMed]
78. Furuta S, Wang JM, Wei S, Jeng YM, Jiang X, Gu B, Chen PL, Lee EY, Lee WH. Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell. 2006;10:13–24. [PubMed]
79. Garcia V, Dominguez G, Garcia JM, Silva J, Pena C, Silva JM, Carcereny E, Menendez J, Espana P, Bonilla F. Altered expression of the ZBRK1 gene in human breast carcinomas. The Journal of pathology. 2004;202:224–32. [PubMed]
80. Garcia V, Garcia JM, Pena C, Silva J, Dominguez G, Rodriguez R, Maximiano C, Espinosa R, Espana P, Bonilla F. The GADD45, ZBRK1 and BRCA1 pathway: quantitative analysis of mRNA expression in colon carcinomas. The Journal of pathology. 2005;206:92–9. [PubMed]
81. Castet A, Boulahtouf A, Versini G, Bonnet S, Augereau P, Vignon F, Khochbin S, Jalaguier S, Cavailles V. Multiple domains of the Receptor-Interacting Protein 140 contribute to transcription inhibition. Nucleic acids research. 2004;32:1957–66. [PMC free article] [PubMed]
82. Chinnadurai G. CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol Cell. 2002;9:213–24. [PubMed]
83. Akiyama H, Sugiyama A, Uzawa K, Fujisawa N, Tashiro Y, Tashiro F. Implication of Trip15/CSN2 in early stage of neuronal differentiation of P19 embryonal carcinoma cells. Brain Res Dev Brain Res. 2003;140:45–56. [PubMed]
84. Wang KC, Cheng AL, Chuang SE, Hsu HC, Su IJ. Retinoic acid-induced apoptotic pathway in T-cell lymphoma: Identification of four groups of genes with differential biological functions. Exp Hematol. 2000;28:1441–50. [PubMed]
85. Hatchell EC, Colley SM, Beveridge DJ, Epis MR, Stuart LM, Giles KM, Redfern AD, Miles LE, Barker A, MacDonald LM, Arthur PG, Lui JC, et al. SLIRP, a small SRA binding protein, is a nuclear receptor corepressor. Mol Cell. 2006;22:657–68. [PubMed]
86. Fernandes I, Bastien Y, Wai T, Nygard K, Lin R, Cormier O, Lee HS, Eng F, Bertos NR, Pelletier N, Mader S, Han VK, et al. Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Mol Cell. 2003;11:139–50. [PubMed]
87. Turner BM. Decoding the nucleosome. Cell. 1993;75:5–8. [PubMed]
88. Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009;138:1019–31. [PMC free article] [PubMed]
89. Yoon HG, Chan DW, Reynolds AB, Qin J, Wong J. N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso. Mol.Cell. 2003;12:723–34. [PubMed]
90. Metivier R, Gallais R, Tiffoche C, Le Peron C, Jurkowska RZ, Carmouche RP, Ibberson D, Barath P, Demay F, Reid G, Benes V, Jeltsch A, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature. 2008;452:45–50. [PubMed]
91. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora I, Pajtler K, Klein-Hitpass L, Kuhfittig-Kulle S, Metzger E, Schule R, et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 2009;69:2065–71. [PubMed]
92. Graham JS, Kaye SB, Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer. 2009;45:1129–36. [PubMed]